scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 14, 2025
Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025
Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025
Read more at globenewswire.com
